JAK2 and myeloproliferative neoplasm: Inhibition of JAK2 signaling in MPN mouse models elicits a reduced phenotypic disease burden, but it does not readily eradicate the MPN-driving and MPN-initiating cells, reminiscent of JAK2 inhibitor effects in human MPN (67–69).